Protein-protein interactions as targets for small-molecule therapeutics in cancer.
about
Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functionsStructural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designingIdentifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction networkTargeting kinase signaling pathways with constrained peptide scaffolds.TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradationsThe role of HTS in drug discovery at the University of Michigan.Development and validation of a high-content bimolecular fluorescence complementation assay for small-molecule inhibitors of HIV-1 Nef dimerization.PPIMpred: a web server for high-throughput screening of small molecules targeting protein-protein interaction.High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.Increasingly accurate dynamic molecular models of G-protein coupled receptor oligomers: Panacea or Pandora's box for novel drug discovery?Homology Modelling of Human E1 Ubiquitin Activating EnzymeANCHOR: a web server and database for analysis of protein-protein interaction binding pockets for drug discovery.Computational alanine scanning with linear scaling semiempirical quantum mechanical methods.From laptop to benchtop to bedside: structure-based drug design on protein targets.Systematic prediction of human membrane receptor interactions.Challenges and opportunities in targeting the menin-MLL interaction.Self-similarity of human protein interaction networks: a novel strategy of distinguishing proteins.Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?DARC 2.0: Improved Docking and Virtual Screening at Protein Interaction SitesMultiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods.The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.On target? Strategies and progress in the development of therapies for colorectal cancer targeted against WNT signalling.Computational prediction of protein hot spot residues.Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy.Insights into the molecular mechanisms of action of bioportides: a strategy to target protein-protein interactions.Murine ultrasound-guided transabdominal para-aortic injections of self-assembling type I collagen oligomers.Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo.Osteopontin at the Crossroads of Inflammation and Tumor Progression.Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology.Prevent protein interactions to prevent cancer metastasis.
P2860
Q24339544-8874A801-4152-4545-A6FB-97E3CEE0BB03Q27671806-E9B4881D-0B83-4719-9669-83532AC20FBFQ28475117-3CEF32E9-D78A-4D35-AAC4-BD49226146B4Q28533728-18820364-3E2A-49CA-A487-30242435F93CQ30398451-31437B33-B8A8-4108-84D4-B5E0AEEC1BFBQ30663340-4FDF8403-04C2-48A6-8C20-A69C5F50C2F1Q31147980-D378B615-02CE-47B1-BD96-D3E1FD419278Q33552872-19E5C1DA-E94A-4536-95F2-58A204249EECQ33630135-ADD647C2-4EA0-4C08-BFEE-A6650F7D5BFEQ33765623-00FBB8AC-8FC9-4980-8966-4BAFD504725AQ33767121-1A2EE8F7-5FB0-4EF0-B510-4B9A766D4339Q33786739-AD0EA38C-1096-4AFD-A3EB-D5390348BB98Q33957616-64ED80CA-1DCE-4594-BAF3-37FF6501D88FQ34056558-A1A15447-C085-4398-8476-8974B3B593C5Q34153589-99025D0B-812D-4442-805A-3D1A08EADF86Q34789186-55B780A4-318A-4B26-BD47-49163761FABFQ35122366-5A1F6A2F-800B-4A79-AD74-794126CC1D91Q35126910-18963249-9D74-4CC0-8FCC-6D3053259F92Q35687836-7B85565D-4536-4C27-A504-0B711FCEBD9AQ35693426-5982A886-FFB7-4887-87FA-A1225DB10A7AQ35872435-F1E8C29D-E13E-4383-A98A-7B6D39F603C1Q37489930-E3039CCD-30DB-4D02-938A-003A84A04DAAQ37656544-D470D2FE-4E7C-493D-BA82-EDFDF0D7D99BQ37982406-016499D6-546D-450A-B4D9-EA3A1EB348B8Q38157714-0A0B9213-A9EE-44F3-B24A-4E84387298D9Q38563691-63006FAD-3081-43BD-98DD-CF845415BC82Q38765380-734D47BA-DB86-4C2A-A010-14EBE465E8C8Q39006758-3081660B-976E-4CFB-B01A-D0120DAA9CF7Q41099667-56DF32A6-051A-46D9-99A6-E0373CBA7424Q42701435-D12E8A34-0CE6-4E39-8556-7817253765EEQ44474292-A50449B8-6361-4E85-B8DB-02257035FDF8
P2860
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@en
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@nl
type
label
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@en
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@nl
prefLabel
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@en
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@nl
P2093
P2860
P1476
Protein-protein interactions as targets for small-molecule therapeutics in cancer.
@en
P2093
Alex W White
Andrew D Westwell
Ghali Brahemi
P2860
P356
10.1017/S1462399408000641
P577
2008-03-19T00:00:00Z